原文 · 未翻译
Anthropic forms $200 million partnership with the Gates Foundation
We’re partnering with the Gates Foundation to commit $200 million in grant funding, Claude usage credits, and technical support for programs in global health, life sciences, education, and economic mobility over the next four years. These programs will be implemented with partners in the US and around the world.
This commitment is central to Anthropic’s efforts to extend the benefits of AI in areas where markets alone will not. This work is led by our Beneficial Deployments team, which provides Claude credits and engineering support to our partners in the four priority areas mentioned above. The team also develops AI-related public goods, such as public health datasets and evaluation benchmarks, and offers nonprofits and education institutions discounted access to Claude. We’re increasing our investment in beneficial deployments, and plan to share more about our approach to this work, and the impact of the programs we’ve supported. Below, we outline what’s involved in our partnership with the Gates Foundation, including our new initiatives and the work that's already underway.
Global health and life sciences
The largest part of our partnership will focus on improving health outcomes in low- and middle-income countries, where around 4.6 billion people lack access to essential health services. Anthropic will work with the Gates Foundation and others on a range of new and existing programs that will accelerate the development of new vaccines and therapies, and help governments use health data to make faster, better-informed decisions.
As part of this work on healthcare intelligence, we’ll create connectors (which grant Claude direct access to other platforms and tools), benchmarks, and evaluation frameworks that allow researchers, developers, and governments to better understand how AI systems perform on healthcare-related tasks.
In addition, we’ll work with the Gates Foundation to engage health ministries and their implementing partners on how to use health-intelligence data to support decision-making around workforce deployment, supply chain management, and outbreak detection. Together, we will explore how AI can better support frontline health workers and patients in navigating diagnosis, treatment, and medical decision-making.
We’ll also use Claude to advance research on high-burden and neglected diseases. Scientists already use Claude to detect patterns in systematic reviews and large datasets, and to screen potential drug and vaccine candidates. Our partnership with the Gates Foundation will extend this work to overlooked diseases, starting with polio, HPV, and eclampsia/preeclampsia.
Together, we will explore how AI can make it faster and easier for scientists to screen potential vaccine candidates—including vaccines that protect against diseases like polio—computationally before moving into pre-clinical development. This could help shorten the early-stage development timeline. A related effort will use Claude to screen for new therapies for HPV and preeclampsia, which cause cervical cancer and dangerous pregnancy disorders, respectively. HPV causes roughly 350,000 deaths annually, of which 90% are in low- and middle-income countries.